News Search Results
Sep 15, 2025, 09:00 ET New Oova Perimenopause Tracker Tells Women Their Stage of Menopause and More
over 30,000 menstrual cycles, Oova can present to users predictable connections between hormone fluctuations and symptoms including hot flashes, insomnia, and mood changes.
More news about: Oova
Sep 15, 2025, 08:00 ET Johnson & Johnson to showcase industry-leading neuropsychiatry innovations at the 2025 Psych Congress Annual Meeting
is often accompanied by sleep disturbances such as insomnia or hypersomnia, with approximately 60 percent of MDD patients experiencing insomnia symptoms despite being on standard-of-care oral antidepressants.12 Disturbed sleep and insomnia symptoms have a significant impact on a patient's quality
More news about: Johnson & Johnson
Sep 11, 2025, 13:00 ET Insomnia Cookies is Hosting the Biggest PJ Party of the Year with Its Seventh Annual PJ Party Event
including glowsticks, Insomnia Cookies swag and more. Insomnia is partnering with Red Bull at five participating college campus bakeries, providing energy for the night with Red Bull™ Energy Drink Infusions. Founded on a university campus, Insomnia Cookies hosts its
More news about: Insomnia Cookies
Sep 10, 2025, 10:00 ET Health Canada Approves Slenyto® - Extended-Release Melatonin Formulation - as a Prescription Drug for Insomnia in Children with Autism Spectrum disorder and Smith Magenis Syndrome
Canada has granted marketing authorization* for Slenyto®, an Extended-release melatonin minitablet indicated for the treatment of insomnia in children and adolescents aged 2 to <18 years with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome (SMS), where
More news about: Neurim Pharmaceuticals
Sep 10, 2025, 10:00 ET Health Canada Approves Slenyto® - Extended-Release Melatonin Formulation - as a Prescription Drug for Insomnia in Children with Autism Spectrum disorder and Smith Magenis Syndrome
Canada has granted marketing authorization* for Slenyto®, an Extended-release melatonin minitablet indicated for the treatment of insomnia in children and adolescents aged 2 to <18 years with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome (SMS), where
More news about: Neurim Pharmaceuticals
![Partner Therapeutics Receives EMA Approval of IMREPLYS® (sargramostim, rhu GM-CSF) to Treat Exposure to Myelosuppressive Doses of Radiation (Hematopoietic Sub-syndrome of Acute Radiation Syndrome [H-ARS])](https://mma.prnewswire.com/media/633165/PTx_updated_logo.jpg?w=300){kind=logo}
Sep 09, 2025, 13:42 ET Partner Therapeutics Receives EMA Approval of IMREPLYS® (sargramostim, rhu GM-CSF) to Treat Exposure to Myelosuppressive Doses of Radiation (Hematopoietic Sub-syndrome of Acute Radiation Syndrome [H-ARS])
hemorrhage, hypertension, tachycardia, bilirubinemia, hyperglycemia, increased creatinine, hypomagnesemia, edema, pharyngitis, epistaxis, dyspnea, insomnia, anxiety, high glucose, low albuminIn patients with AML–fever, weight loss, nausea, vomiting, anorexia, skin reactions, metabolic laboratory
More news about: Partner Therapeutics, Inc.
Sep 09, 2025, 11:09 ET PCORI awards new patient-centered CER to support informed health care decisions
challenges Among the newly awarded patient-centered CER studies, two focus on sleep health. One will compare treatment approaches for insomnia and another for sleep apnea — both common conditions affecting millions of adults. Another study will compare approaches including nondrug
More news about: Patient-Centered Outcomes Research Institute
Sep 08, 2025, 03:15 ET Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025
group. Most TEAEs were mild to moderate in severity. The most common TEAEs7 were pollakiuria, insomnia, salivary hypersecretion, urinary urgency and blurred vision. Events of insomnia largely occurred and resolved within the first week of dosing. Events of blurred vision were mostly mild and
More news about: Alkermes plc
Sep 08, 2025, 00:01 ET Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025
believed to help maintain a more stable state of wakefulness. From the perspective of inhibiting orexinergic neuron activity, Eisai has developed the insomnia treatment DAYVIGO ® (generic name: lemborexant) an orexin receptor antagonist that is available in more than 25 countries worldwide. Furthermore,
More news about: Eisai Inc.
Sep 05, 2025, 08:00 ET Idorsia to collaborate with two leading academic medical centers to launch IMPACT-HTN - a US initiative to transform care for patients with difficult-to-control hypertension
a highly experienced team of dedicated professionals, covering all disciplines from bench to bedside; QUVIVIQ™ (daridorexant), a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern; strong partners to maximize the value of our portfolio; a promising
More news about: Idorsia Pharmaceuticals Ltd.
Sep 04, 2025, 10:05 ET Former U.S. Federal CIO Joins Nox Health Board, Bringing Proven Government Leadership to Drive Healthcare Innovation and Cost Savings
"Her perspective will help shape the future of our work as we grow our capabilities in diagnostic solutions, prescription therapeutics for chronic insomnia, and comprehensive sleep care management." "I am honored to join the Nox Board of Directors and support its mission," said Clare
More news about: Nox Health
Sep 03, 2025, 19:30 ET Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025
people diagnosed with narcolepsy type 1 (NT1) and the Phase IV clinical study (SELENADE Study) investigating the effect of lemborexant in people whose insomnia was comorbid with depressive episodes of major depressive disorder and bipolar disorder (Poster 3-133). The company will also host a symposium introducing
More news about: Eisai Inc.
Sep 03, 2025, 10:00 ET Is Indoor Mold Affecting Your Mental Health?
ailment during her 40+ years in the healthcare industry. As the skin breakouts continued to spread to her head and legs, she then started experiencing insomnia, fatigue, anxiety, depression, dizziness and headaches. When fevers, muscle twitching, and body pain began, Cheske knew that the cause of her physical
More news about: Mold Hunt
Aug 29, 2025, 11:21 ET Lifezoom Updates: Refining Efficient Light Therapy Products Based on Customer Insights
Pan, R., Zhang, G., Deng, F., Lin, W., & Pan, J. (2023). Effects of red light on sleep and mood in healthy subjects and individuals with insomnia disorder. Frontiers in Psychiatry, 14, Article 1200350.
More news about: Lifezoom
Aug 29, 2025, 01:23 ET UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress
trace aortic regurgitation, which are considered physiologic). Common (≥1/100 to <1/10): Bronchitis, abnormal behaviour, aggression, agitation, insomnia, mood swings, ataxia, hypotonia, lethargy, seizure, status epilepticus, tremor, constipation, salivary hypersecretion, weight decreased and blood prolactin
More news about: UCB
Aug 29, 2025, 01:15 ET UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress
trace aortic regurgitation, which are considered physiologic). Common (≥1/100 to <1/10): Bronchitis, abnormal behaviour, aggression, agitation, insomnia, mood swings, ataxia, hypotonia, lethargy, seizure, status epilepticus, tremor, constipation, salivary hypersecretion, weight decreased and blood prolactin
More news about: UCB
Aug 18, 2025, 07:00 ET In a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag Disorder
Rajaratnam, S., Polymeropoulos, M., Fisher, D., Roth, T., Scott, C., Birznieks, G., Klerman, E. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials. Lancet 2009; 373(9662):482-91. See also Cardinali, D., Golombek,
More news about: Vanda Pharmaceuticals Inc.
Aug 13, 2025, 17:46 ET Global Digital Therapeutics Market Experiencing Rapid Growth at a CAGR of ~28% by 2032 Amid Rising Demand for Personalized Healthcare| DelveInsight
robust digital health ecosystems. The US leads in regulatory clarity, with the FDA approving multiple DTx solutions for conditions like diabetes, insomnia, and mental health. The region also benefits from significant investment activity and partnerships between DTx developers and major pharmaceutical
More news about: DelveInsight Business Research, LLP
Aug 13, 2025, 08:07 ET SentientLight Seeks US$10M After Peer-Reviewed PEMF Study Validates Non-Drug Pain Relief
for arthritis, insomnia, and Lyme disease exceed US$38.7 billion: Rheumatoid arthritis therapeutics: US$25 billion in 2023, projected US$36.4 billion by 2030Insomnia therapeutics:
More news about: SentientLight
Jul 15, 2025, 04:45 ET Youthful Narrative Bridges Traditional Chinese Medicine to Global Audience
knowledge from the Compendium of Materia Medica, and debate sessions addressing globally relevant health concerns such as insomnia management and emotional regulation. Related social media campaigns like #Late-Night Recovery Guide generated widespread discussion, transforming
More news about: Dong-E-E-Jiao
Jul 02, 2025, 08:38 ET Star Sleep & Wellness Opens New Location in Mansfield Expanding Comprehensive Sleep Care to Better Serve the Growing DFW Community
Star Sleep & Wellness is dedicated to providing compassionate, evidence-based care for sleep disorders including obstructive sleep apnea, insomnia, and restless leg syndrome. With six locations across the DFW metroplex, their mission is to help every patient reclaim a healthy, energized life through
More news about: Star Sleep & Wellness Mansfield
Jun 27, 2025, 08:30 ET Neurocrine Biosciences Presents New Post-Hoc Data Analyses from KINECT®-HD Study Demonstrating Significant Reduction in Disease Burden with INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea
known safety profile of valbenazine. The most common adverse reactions in patients with HD included somnolence and sedation, urticaria, rash and insomnia. View the complete study results from the Phase 3 KINECT-HD study published in The Lancet Neurology
More news about: Neurocrine Biosciences, Inc.
Jun 26, 2025, 08:00 ET Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression
Symptoms of PPD include hallmarks of major depression, including, but not limited to, sadness, depressed mood, loss of interest, change in appetite, insomnia, sleeping too much, fatigue, difficulty thinking/concentrating, excessive crying, fear of harming the baby/oneself, and/or thoughts of death or suicide.
More news about: Lipocine Inc.
Jun 23, 2025, 10:30 ET Coffee Substitutes Market to Grow from USD 16.21 Billion to USD 24.05 Billion by 2032 - Meticulous Research®
widespread behavioral changes among consumers worldwide. Studies demonstrate that regular coffee consumption contributes to anxiety disorders and insomnia, creating sustained demand for coffee substitutes that provide energy-boosting benefits without negative side effects. Natural and Plant-Based
More news about: Meticulous Market Research Pvt. Ltd.
Jun 23, 2025, 08:00 ET Lipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO™) as a Treatment for Postpartum Depression on July 9, 2025
Symptoms of PPD include hallmarks of major depression, including, but not limited to, sadness, depressed mood, loss of interest, change in appetite, insomnia, sleeping too much, fatigue, difficulty thinking/concentrating, excessive crying, fear of harming the baby/oneself, and/or thoughts of death or suicide.
More news about: Lipocine Inc.